Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain


All attempts at treating strokes by pharmacologically reducing the human brain’s vulnerability to ischaemia have failed, leaving stroke as a leading cause of death, disability and massive socioeconomic loss worldwide1. Over decades, research has failed to translate over 1,000 experimental treatments from discovery in cells and rodents to use in humans2,3,4, a scientific crisis that gave rise to the prevailing belief that pharmacological neuroprotection is not feasible or practicable in higher-order brains. To provide a strategy for advancing stroke therapy, we used higher-order gyrencephalic non-human primates, which bear genetic, anatomical and behavioural similarities to humans5,6 and tested neuroprotection by PSD-95 inhibitors—promising compounds that uncouple postsynaptic density protein PSD-95 from neurotoxic signalling pathways7,8,9,10. Here we show that stroke damage can be prevented in non-human primates in which a PSD-95 inhibitor is administered after stroke onset in clinically relevant situations. This treatment reduced infarct volumes as gauged by magnetic resonance imaging and histology, preserved the capacity of ischaemic cells to maintain gene transcription in genome-wide screens of ischaemic brain tissue, and significantly preserved neurological function in neurobehavioural assays. The degree of tissue neuroprotection by magnetic resonance imaging corresponded strongly to the preservation of neurological function, supporting the intuitive but unproven dictum that integrity of brain tissue can reflect functional outcome. Our findings establish that tissue neuroprotection and improved functional outcome after stroke is unequivocally achievable in gyrencephalic non-human primates treated with PSD-95 inhibitors. Efforts must ensue to translate these findings to humans.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Treatment with Tat-NR2B9c attenuates infarct volume in NHPs subjected to MCAO(−)p.
Figure 2: Treatment with Tat-NR2B9c preserves capacity for transcription in NHPs subjected to stroke.
Figure 3: Treatment with Tat-NR2B9c at 60 min improves MRI and functional outcome after a 4.5-h MCAO(−)p.
Figure 4: Treatment with Tat-NR2B9c at 3 h improves MRI and functional outcome after a 3.5-h MCAO(+)p.

Accession codes

Primary accessions

Gene Expression Omnibus

Data deposits

Microarray data are deposited in National Center for Biotechnology Information (NCBI) Gene Expression Omnibus under accession number GSE35589.


  1. 1

    Roger, V. L. et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 123, e18–e209 (2011)

    Article  Google Scholar 

  2. 2

    Anon The bitterest pill. Nature 444, 532–533 (2006)

    Article  Google Scholar 

  3. 3

    O’Collins, V. E. et al. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467–477 (2006)

    Article  Google Scholar 

  4. 4

    Sacchetti, M. L. Is it time to definitely abandon neuroprotection in acute ischemic stroke? Stroke 39, 1659–1660 (2008)

    Article  Google Scholar 

  5. 5

    Courtine, G. et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? Nature Med. 13, 561–566 (2007)

    CAS  Article  Google Scholar 

  6. 6

    Enard, D., Depaulis, F. & Roest Crollius, H. Human and non-human primate genomes share hotspots of positive selection. PLoS Genet. 6, e1000840 (2010)

    Article  Google Scholar 

  7. 7

    Aarts, M. et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298, 846–850 (2002)

    ADS  CAS  Article  Google Scholar 

  8. 8

    Sattler, R. et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284, 1845–1848 (1999)

    CAS  Article  Google Scholar 

  9. 9

    Soriano, F. X. et al. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J. Neurosci. 28, 10696–10710 (2008)

    CAS  Article  Google Scholar 

  10. 10

    Sun, H. S. et al. Effectiveness of PSD-95 inhibitors in permanent and transient focal ischemia in the rat. Stroke 39, 2544–2553 (2008)

    CAS  Article  Google Scholar 

  11. 11

    Roitberg, B. et al. Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical study. Neurol. Res. 25, 68–78 (2003)

    Article  Google Scholar 

  12. 12

    Fisher, M. The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc. Dis. 17 (suppl. 1). 1–6 (2004)

    Article  Google Scholar 

  13. 13

    Bardutzky, J. et al. Characterizing tissue fate after transient cerebral ischemia of varying duration using quantitative diffusion and perfusion imaging. Stroke 38, 1336–1344 (2007)

    Article  Google Scholar 

  14. 14

    Fisher, M. et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40, 2244–2250 (2009)

    Article  Google Scholar 

  15. 15

    Committee, S. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752–2758 (1999)

    Article  Google Scholar 

  16. 16

    Kornau, H. C., Schenker, L. T., Kennedy, M. B. & Seeburg, P. H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269, 1737–1740 (1995)

    ADS  CAS  Article  Google Scholar 

  17. 17

    Cui, H. et al. PDZ protein interactions underlying NMDA-receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J. Neurosci. 27, 9901–9915 (2007)

    CAS  Article  Google Scholar 

  18. 18

    Bratane, B. T. et al. Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke 42, 3265–3270 (2011)

    CAS  Article  Google Scholar 

  19. 19

    Marshall, J. W. & Ridley, R. M. Assessment of cognitive and motor deficits in a marmoset model of stroke. ILAR J. 44, 153–160 (2003)

    CAS  Article  Google Scholar 

  20. 20

    Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659–661 (2008)

    CAS  Article  Google Scholar 

  21. 21

    Brott, T. et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20, 864–870 (1989)

    CAS  Article  Google Scholar 

  22. 22

    Johnston, K. C. et al. Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome? Stroke 38, 1820–1825 (2007)

    Article  Google Scholar 

  23. 23

    Hand, P. J. et al. MR diffusion-weighted imaging and outcome prediction after ischemic stroke. Neurology 66, 1159–1163 (2006)

    CAS  Article  Google Scholar 

  24. 24

    Yanagihara, T. Experimental stroke in gerbils: effect on translation and transcription. Brain Res. 158, 435–444 (1978)

    CAS  Article  Google Scholar 

  25. 25

    Hacke, W. et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363, 768–774 (2004)

    Article  Google Scholar 

  26. 26

    Hacke, W. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317–1329 (2008)

    CAS  Article  Google Scholar 

  27. 27

    Sanossian, N. et al. Simultaneous ring voice-over-Internet phone system enables rapid physician elicitation of explicit informed consent in prehospital stroke treatment trials. Cerebrovasc. Dis. 28, 539–544 (2009)

    Article  Google Scholar 

  28. 28

    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581–1587 (1995)

    Article  Google Scholar 

  29. 29

    Savitz, S. I. & Fisher, M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann. Neurol. 61, 396–402 (2007)

    CAS  Article  Google Scholar 

  30. 30

    Savitz, S. I. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol. 205, 20–25 (2007)

    CAS  Article  Google Scholar 

  31. 31

    Findlay, J. M., Macdonald, R. L., Weir, B. K. & Grace, M. G. Surgical manipulation of primate cerebral arteries in established vasospasm. J. Neurosurg. 75, 425–432 (1991)

    CAS  Article  Google Scholar 

  32. 32

    Kosior, J. C. & Frayne, R. PerfTool: a software platform for investigating bolus-tracking perfusion imaging quantification strategies. J. Magn. Reson. Imaging 25, 653–659 (2007)

    Article  Google Scholar 

  33. 33

    Stewart, C. B. & Disotell, T. R. Primate evolution – in and out of Africa. Curr. Biol. 8, R582–R588 (1998)

    CAS  Article  Google Scholar 

  34. 34

    Kobasa, D. et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445, 319–323 (2007)

    ADS  CAS  Article  Google Scholar 

  35. 35

    Gibbs, R. A. et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222–234 (2007)

    CAS  Article  Google Scholar 

  36. 36

    Draghici, S. et al. A systems biology approach for pathway level analysis. Genome Res. 17, 1537–1545 (2007)

    CAS  Article  Google Scholar 

  37. 37

    Marshall, J. W. & Ridley, R. M. Assessment of functional impairment following permanent middle cerebral artery occlusion in a non-human primate species. Neurodegeneration 5, 275–286 (1996)

    CAS  Article  Google Scholar 

Download references


This work was supported by grants to M.T. from the Canadian Stroke Network and the Heart and Stroke Foundation of Ontario, grant NA 6988. D.J.C. is a recipient of a Canadian Stroke Network postdoctoral research fellowship. M.T. is a Canada Research Chair (Tier 1) in Translational Stroke Research. We thank M. Madden, B. Maloo, A. Goldstein, B. Madeira, W. Foltz and Z. Lu for assistance. We thank M. Salter and M. Hill for a review of the manuscript.

Author information




D.C. and M.T. performed the experimental procedures, collected and analysed the data and drafted the manuscript. L.T. performed experimental procedures and data collection.

Corresponding author

Correspondence to Michael Tymianski.

Ethics declarations

Competing interests

M.T. is president of NoNO Inc., a biotechnology company founded to develop PSD-95 inhibitors discovered in his research laboratory.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1-6 with legends, Supplementary Methods, a Supplementary Discussion, Supplementary Tables 1-4 and Supplementary References. (PDF 5966 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cook, D., Teves, L. & Tymianski, M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483, 213–217 (2012).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing